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The intracellular pathogenMycobacterium tuberculosis is the causative agent of
tuberculosis, which is a leading cause of mortality worldwide. The survival of
M. tuberculosis in host macrophages through long-lasting periods of persistence
depends, in part, on breaking down host cell lipids as a carbon source. The
critical role of fatty-acid catabolism in this organism is underscored by the
extensive redundancy of the genes implicated in -oxidation (100 genes). In a
previous study, the enzymology of the M. tuberculosis l-3-hydroxyacyl-CoA
dehydrogenase FadB2 was characterized. Here, the crystal structure of this
enzyme in a ligand-free form is reported at 2.1 A˚ resolution. FadB2 crystallized
as a dimer with three unique dimer copies per asymmetric unit. The structure of
the monomer reveals a dual Rossmann-fold motif in the N-terminal domain,
while the helical C-terminal domain mediates dimer formation. Comparison
with the CoA- and NAD+-bound human orthologue mitochondrial hydroxyacyl-
CoA dehydrogenase shows extensive conservation of the residues that mediate
substrate and cofactor binding. Superposition with the multi-catalytic homo-
logue M. tuberculosis FadB, which forms a trifunctional complex with the
thiolase FadA, indicates that FadB has developed structural features that
prevent its self-association as a dimer. Conversely, FadB2 is unable to substitute
for FadB in the tetrameric FadA–FadB complex as it lacks the N-terminal
hydratase domain of FadB. Instead, FadB2 may functionally (or physically)
associate with the enoyl-CoA hydratase EchA8 and the thiolases FadA2, FadA3,
FadA4 or FadA6 as suggested by interrogation of the STRING protein-network
database.
1. Introduction
The bacterial pathogen Mycobacterium tuberculosis (Mtb) is
the ninth leading cause of mortality worldwide and remains
the foremost cause of death caused by a single infectious agent
(World Health Organization, 2018). Over millennia of co-
evolution with its human host (Gagneux, 2012), the tubercle
bacillus has fine-tuned strategies for survival inside host
macrophages, its most frequent niche. Infected macrophages
trigger the immune system to form a granuloma, a cluster of
infected macrophages surrounded by foamy macrophages,
lymphocytes and a fibrous cuff (Russell, 2007). Inside the
granuloma, Mtb evades immune clearance and enters a long-
lasting latency or persistence state. An obvious drawback of
this survival strategy is that the organism must cope with an
environment in which nutrient supply is scarce and, as a key
adaptation, Mtb utilizes host cell lipids as a carbon source
(Pandey & Sassetti, 2008; Lee et al., 2013; Bonds & Sampson,
2018). Recent evidence shows that Mtb degrades host cell
cholesterol during persistence (Pandey & Sassetti, 2008;
Wipperman et al., 2014) and that the inhibition of cholesterol
degradation could provide a potential route to control the
growth of Mtb in macrophages (VanderVen et al., 2015).
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The products of cholesterol catabolism include acyl-CoA fatty
acids, which are broken down by -oxidation to acetyl-CoA,
feeding into the tricarboxylic acid cycle and gluconeogenesis
via the glyoxylate shunt (Pandey & Sassetti, 2008).
The -oxidation pathway was first described for Escherichia
coli (Black & DiRusso, 1994), which has a single set of genes
in the fatty-acid degradation (fad) operon (Mun˜oz-Elı´as &
McKinney, 2006). The pathway requires five distinct enzymatic
activities: attachment of (saturated) fatty acids to coenzyme A
(CoA) by FadD (acyl-CoA synthetase), followed by catabo-
lism of the CoA-linked acyl chains through an iterative cycle
of four reactions (Fig. 1), with each iteration removing two C
atoms from the acyl chain. The cycle begins by introducing a
double bond between C2 and C3 ( and  positions), which is
followed by hydroxylation (step 2) and hydroxy dehydro-
genation at C3 (step 3); the cycle is completed by the thiolytic
cleavage of 3-ketoacyl-CoA to give acyl-CoA and acetyl-CoA
(step 4).
In contrast to the single set of fad genes in E. coli (Mun˜oz-
Elı´as & McKinney, 2006), the genome of Mtb includes about
100 genes linked to -oxidation (Cole et al., 1998). This
repertoire includes five genes with the fadB designation: fadB
(Rv0860) and fadB2–fadB5. Mtb FadB is a multi-catalytic
enzyme that catalyses both the hydration and the 3-hydroxy
dehydrogenation steps in the -oxidation cycle (Venkatesan &
Wierenga, 2013). In contrast, FadB2 (Rv0468) and FadB3
(Rv1715) are smaller, monofunctional enzymes that encom-
pass only a hydroxyacyl-CoA dehydrogenase (HAD) domain.
The amino-acid sequences of FadB4 (Rv3141) and FadB5
(Rv1912c) are similar to each other, but show a distinctly
lower similarity to the other three enzymes (Taylor et al.,
2010). In a previous study, we characterized the enzymatic
properties of Mtb FadB2, demonstrating that it harbours
3-hydroxy dehydrogenase activity as well as catalysing the
reverse reaction from acetoacetyl-CoA to 3-hydroxyacyl-CoA
(Taylor et al., 2010). Genetic knockout of fadB2 in M. smeg-
matis had no discernible phenotype, in line with the presence
of several fadB homologues in the mycobacterial genome. The
expression of FadB2 has been observed to be moderately up-
regulated under acidic conditions (Fisher et al., 2002), whereas
in an in vitro activity assay low pH favoured the reverse
reaction, converting acetoacetyl-CoA to 3-hydroxyacyl-CoA,
while maximal activity for the forward reaction occurred at pH
10 (Taylor et al., 2010).
Here, we report the crystal structure ofMtb FadB2 at 2.1 A˚
resolution in the ligand-free form and we use the structure to
undertake a structural comparison of mycobacterial FadB
homologues.
2. Materials and methods
2.1. Cloning, expression and purification of Mtb FadB2
The protocol for obtaining His-tagged recombinant FadB2
has been described previously (Taylor et al., 2010). Briefly,
the gene sequence of fadB2 (Rv0468) was amplified fromMtb
H37Rv chromosomal DNA by PCR and the amplified DNA
fragment was ligated into the NdeI and HindIII restriction
sites of the pET-28b plasmid vector (Novagen). The resulting
expression plasmid was heat-shock transformed into E. coli
C43 (DE3) cells, which were grown on LB agar plates,
selecting for transformants with 25 mg ml1 kanamycin.
Bacterial colonies were propagated in overnight liquid
cultures (5 ml LB, 37C, 180 rev min1) and used to inoculate
bulk cultures (1 l Terrific Broth, 25 mg ml1 kanamycin). Bulk
cultures were grown to an OD600 of 0.6 (37
C, 180 rev min1)
and protein expression was induced by adding IPTG (1 mM
final concentration). The induced cultures were incubated
(16C, 180 rev min1) and the cells were harvested after
12–14 h by centrifugation (4000 rev min1, 4C). Cleared cell
extracts were prepared in lysis buffer (0.05M sodium phos-
phate pH 8.0, 0.3M NaCl, 10 mM imidazole) supplemented
with EDTA-free protease-inhibitor cocktail (Roche) and were
purified using Ni–NTA affinity chromatography. The protein
was eluted using a step gradient increasing the imidazole
concentration in the lysis buffer to 50 mM, 130 mM, 150 mM
and 1M. Eluted fractions were analysed by SDS–PAGE. The
130 and 150 mM fractions were pooled, dialysed into 25 mM
HEPES pH 8, 300 mM NaCl, 10%(v/v) glycerol and concen-
trated by ultrafiltration (Amicon, 10 kDa cutoff) to a final
concentration of 10 mg ml1.
2.2. Crystallization
Crystals were obtained by sitting-drop vapour diffusion
using the commercial JCSG-plus screen (Molecular Dimen-
sions) in a 96-well format and using a liquid-handling robot
(Mosquito, TTP Labtech) to pipet drops of 150 nl protein
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Figure 1
Schematic representation of the reaction cycle for the -oxidation of
CoA-linked fatty acids. In each cycle the CoA-linked acyl chain is
shortened from C2n to C2n2.
solution plus 150 nl reservoir solution. Diffraction-quality
crystals appeared over a reservoir consisting of 0.2M ammo-
nium citrate dibasic, 20%(w/v) polyethylene glycol 3350. In
preparation for X-ray diffraction experiments, crystals were
immersed for a few seconds in reservoir solution supple-
mented with 10%(v/v) ethylene glycol, mounted in nylon
loops and quenched in liquid nitrogen.
2.3. Structure determination
X-ray diffraction data were recorded on beamline I04-1 at
Diamond Light Source (Table 1). Initial phases were obtained
by molecular replacement with Phaser (McCoy et al., 2007)
using diffraction data to 3.5 A˚ resolution and the structure of
the monomer of 3-hydroxybutyryl-CoA dehydrogenase from
Clostridium butyricum as a search model (PDB entry 4kue;
Kim et al., 2014). Following alignment between the search and
target sequences (43% identity), non-identical side chains
were trimmed to the -carbon using CHAINSAW from CCP4
(Winn et al., 2011). Analysis of the Matthews volume
suggested that the asymmetric unit could contain up to eight
FadB2 monomers. However, the successive placement of six
copies of the search model into the asymmetric unit generated
a complete structure. Phaser Z-scores after translation search
of 8.9 to 32.3 for copies 1 to 6, respectively, provided confi-
dence that a correct solution had been identified. The
A-weighted 2Fo  Fc map showed clear density for many
nonconserved side chains, allowing the structural model to be
unequivocally completed and refined with Coot (Emsley et al.,
2010) and REFMAC5 (Murshudov et al., 2011). Temperature
factors were modelled using TLS refinement in combination
with individual B factors, while noncrystallographic restraints
were imposed across the six independent copies in the asym-
metric unit. Comparison of ‘medium’ versus ‘loose’ or no NCS
restraints produced virtually identical R factors and root-
mean-square deviations between NCS-related molecules,
while employing ‘tight’ restraints increased the free R factor
from 19% to 20.7%. Therefore, ‘medium’ restraints were
adopted for the final refinement. The final model has good
stereochemistry (Table 1) and R factors of 19.0% for the
working set and 20.1% for the test set. X-ray diffraction data-
collection and refinement statistics are reported in Table 1.
Coordinates and structure factors have been deposited in the
Protein Data Bank (PDB) with accession code 6hrd.
3. Results and discussion
3.1. X-ray crystal structure of Mtb FadB2
In a previous study, we characterized the enzymology of
Mtb FadB2 (Rv0468) and showed that this enzyme catalyses
the oxidation of 3-hydroxyacyl-CoA to acetoacetyl-CoA
(Taylor et al., 2010). We have now determined the crystal
structure of apo Mtb FadB2 at 2.1 A˚ resolution (Table 1;
Supplementary Fig. S1). The structural model represents
amino-acid residues 3–286 of FadB2 (Fig. 2a) and does not
include the disordered N-terminal hexahistidine purification
tag. The asymmetric unit contained six protomers of FadB2
assembled into three dimers (Fig. 2b). Given the resolution
limit and the number of unique copies, noncrystallographic
symmetry restraints were applied during coordinate and
temperature-factor refinement.
The overall structure of the FadB2 monomer (Fig. 2a)
conforms closely to the paradigm of previously solved
monofunctional l-3-hydroxylacyl-CoA dehydrogenases. The
enzyme presents a two-domain architecture consisting of an
N-terminal domain containing a dual Rossmann fold (residues
3–189) and a smaller C-terminal domain (residues 190–286;
Figs. 2a and 3). The duplicated  motif of the Rossmann
fold consists of the secondary-structure elements 1–1–2
and 4–4–5 (Fig. 2a). Helices 2, 3 and strand 3 are
spliced in between the two  motifs. Strand 6, strand 7
and (the antiparallel) strand 8 complete the central parallel
-sheet, with the latter marking the C-terminal boundary of
the N-terminal domain. The C-terminal domain consists of a
five-helix bundle (helices 7–11; Fig. 2a). The domain
boundary is located in the loop between strand 8 and helix 7
(Figs. 2a and 3). The active site is located in the cleft between
the N- and C-terminal domains.
FadB2 crystallized as a dimer (Figs. 2c and 2d), consistent
with the structures of human mitochondrial HAD (PDB entry
1f0y; Barycki et al., 2000) and of C. butyricum HAD (PDB
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Table 1
X-ray diffraction data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
X-ray diffraction data
PDB entry 6hrd
Beamline I04-1, Diamond Light Source
Wavelength (A˚) 0.92819
Space group P43
a, b, c (A˚) 90.22, 90.22, 284.7
Molecules per asymmetric unit 6
Resolution (A˚) 90.2–2.11 (2.16–2.11)
Rmerge† (%) 9.9 (104)
Total reflections 881634
Unique reflections 129955
hI/(I)i 13.8 (1.6)
Completeness (%) 100 (100)
Multiplicity 6.8 (5.7)
CC1/2† 0.998 (0.583)
Refinement
Resolution range 90.22–2.11
Unique reflections 123371
Rcryst/Rfree (%) 19.0/22.1
No. of non-H atoms
Total 13117
Protein 12675
Solvent 424 [water], 18 [glycerol]
R.m.s.d., bonds (A˚) 0.013
R.m.s.d., angles () 1.63
B factors (A˚2)
Wilson 39.9
Average overall 42.2
Average protein 42.4
Average solvent 36.4
R.m.s.d. for B factors 1.18
Ramachandran plot‡
Favoured region (%) 96.7
Disallowed (%) 0.18 [3 residues]
† CC1/2 (the correlation between half data sets) is defined in Karplus & Diederichs
(2012). ‡ Ramachandran plot statistics were calculated using MolProbity (Chen et al.,
2010).
entry 4kue; Kim et al., 2014). The dimer interface is formed
solely by the C-terminal domain. The solvent-accessible
surface (SAS) buried upon dimerization of FadB2 is 1500 A˚
per monomer. The interface-analysis software PISA (Kris-
sinel, 2015) calculated a complex-formation significance score
(CSS) of 0.94, suggesting that the dimer is stable in the solu-
tion state. While we did not experimentally verify the oligo-
meric state of FadB2 in solution, both analysis of the dimer
interface and the self-assembly of the structural homologues
suggest that FadB2 functions as a dimer in vivo.
3.2. Comparison with other FadB structures
FadB2 is a monofunctional enzyme that mediates 3-hydroxy-
acyl-CoA dehydrogenase activity (Taylor et al., 2010) and
superimposes closely with the corresponding human enzyme,
mitochondrial HAD (PDB entry 1f0y; Barycki et al., 2000),
aligning 188 C atoms with a root-mean-square deviation
(r.m.s.d.) of 1.16 A˚. There is also a close match with the
structure of C. butyricum HAD (PDB entry 4kue; Kim et al.,
2014; 277 C atoms, r.m.s.d. of 0.99 A˚). Both orthologues also
crystallized as dimers.
In contrast, the multi-catalytic Mtb FadB combines an
N-terminal enoyl-CoA hydratase domain with a C-terminal
HAD segment (Fig. 4a). Furthermore, FadB forms a
noncovalent, heterotetrameric complex with the dimeric
ketoacyl-CoA thiolase FadA (PDB entry 4b3h; Venkatesan &
Wierenga, 2013; Supplementary Fig. S2). Thus, this complex
mediates three of the four reaction steps in -oxidation
(Fig. 1), and there is evidence for substrate channelling
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Figure 2
Ribbon representation of the structure ofMtb FadB2. (a) The FadB2 monomer consists of an N-terminal domain (purple–red) with two Rossmann-fold
motifs (1–1–2 and 4–4–5; cyan), and an -helical bundle in the C-terminal domain (7–11; magenta). The location of the active site is indicated
with translucent spheres for CoA and NAD+ (derived from the superposition with ligand-bound HsHAD; PDB entry 1f0y; Barycki et al., 2000).
Secondary-structure elements are labelled according to the secondary-structure analysis by DSSP (Kabsch & Sander, 1983) as shown in Fig. 3. The
locations of the N- and C-termini are indicated with the corresponding residue numbers (1 and 287; bold italics), as is the domain boundary (190). (b)
Representation of the three FadB2 dimers in the asymmetric unit of the crystal structure. (c, d) Two orthogonal views of the FadB2 dimer (chains A and
B). The dimer interface is formed entirely by the helical C-terminal domain (helices 7–11).
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Figure 3
Multiple sequence alignment of FadB homologues. Secondary-structure elements of M. tuberculosis FadB2 and FadB (determined by DSSP; Kabsch &
Sander, 1983) are indicated above and below the sequences, respectively, with ,  and  indicating -helices, -strands and 310-helices, respectively. The
boundary between the N- and C-terminal domains is indicated as N | C. Conserved residues are highlighted in red text surrounded by blue boxes;
residues that are identical across the alignment are shown in white on a red background. The @ and ^ symbols indicate residues in human l-3-
hydroxyacyl-CoA dehydrogenase (HsHAD; PDB entry 1f0y; Barycki et al., 2000) within a 4.0 A˚ radius of the CoA and NAD+ ligands, respectively.
FadB2, M tuberculosis FadB2 (Rv0468); FadB3, M tuberculosis FadB3 (Rv1715); FadB_Pfr, Pseudomonas fragi fatty-acid oxidation complex FadB
(-subunit; WP_010656816); FadB, Mtb trifunctional fatty-acid oxidation protein complex (Rv0860; PDB entry 4b3h; Venkatesan & Wierenga, 2013).
Inset: alignment of C-terminal residues 629–720 of FadB with residues 190–268 of FadB2 as derived from the structural superposition shown in Fig. 4(e).
between the catalytic sites of the complex (Eaton et al., 1996;
Ishikawa et al., 2004). Similar multifunctional complexes have
been described in rat (Kasaragod et al., 2010), the model plant
Arabidopsis thaliana (Arent et al., 2010) and the prokaryote
Pseudomonas fragi (Ishikawa et al., 2004).
When FadB2 is aligned with FadB by secondary-structure
matching, FadB2 overlaps with the C-terminal HAD segment
of Mtb FadB. In this superposition, the N- and C-terminal
domains of FadB2 match the HAD-N and HAD-C1 domains
of FadB, respectively (Fig. 4b), while the HAD-C2 domain of
FadB remains without a counterpart. However, when the
FadB monomer is superimposed onto the FadB2 dimer, the
C-terminal domain of the second monomer matches the
helices of the HAD-C2 domain of FadB (Figs. 4c, 4d, 4e and
the inset in Fig. 3). Furthermore, the HAD-C1 and HAD-C2
domains are superimposable onto each other (57 C atoms
aligned, r.m.s.d. of 1.55 A˚; Fig. 4f), suggesting that the
HAD-C1 and HAD-C2 domains may have arisen from gene
duplication.
In the structural context of FadB, the HAD-C2 domain has
no obvious role in either catalysis or assembly of the trifunc-
tional FadA–FadB heterotetramer (Supplementary Fig. S2).
The largest share (75%) of the surface area buried in the
interface with FadA is contributed by the hydratase domain of
FadB, complemented by the contacts of eight residues in the
HAD-C1 domain (21% of the surface buried in the inter-
face), while only three residues of the HAD-C2 domain
contact FadA. Similarly, the location of the HAD-C2 domain
relative to the substrate-binding or cofactor-binding sites does
not suggest that the HAD-C2 domain can contact the ligands.
Therefore, it is not immediately clear what drove the apparent
gene-duplication event that gave rise to the C2 domain. Since
the five-helix bundle of the C-terminal domain mediates the
dimerization of FadB2, one wonders whether FadB could self-
assemble into dimers if the HAD-C2 domain were not present.
Indeed, when omitting this domain, it is possible to construct a
FadB dimer in analogy to the FadB2 dimer (i.e. mediated
by dimerization of the HAD-C1 domain), although this
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Figure 4
Structural comparison between FadB and the FadB2 dimer. (a) Ribbon diagram ofMtb FadB (PDB entry 4b3h; Venkatesan &Wierenga, 2013) coloured
according to its structural domains. HAD, 3-hydroxyacyl dehydrogenase domain. (b) The same as in (a), but superimposed onMtb FadB2 (magenta) by
secondary-structure matching. Light blue and yellow spheres indicate the location of the active site in the HAD domain. (c, d) Adding the second
protomer of the FadB2 dimer demonstrates the superposition of the FadB2 C-terminal domain (grey) with the HAD-C2 domain of FadB. The FadB
hydratase domain is omitted from the view. (e) Close-up view of the central area of the FadB2 dimer and its match with the HAD-C1 and HAD-C2
domains of FadB. ( f ) Superposition of the HAD-C1 and HAD-C2 domains of FadB. Residues numbers of the N- and C-terminal residues of the
structural fragments are indicated in addition to secondary-structure labels.
hypothetical dimer incurs partial steric overlap between the
hydratase domains. Nevertheless, a small rotation about the
axis of the linker helix between the hydratase and HAD
domains would resolve the overlap. Thus, it appears that an
evolutionary driver of integrating the HAD-C2 domain within
the polypeptide chain of FadB is to prevent the self-
association of FadB into dimers, so that the surface of the
hydratase domain remains available for binding to the FadA
dimer.
3.3. Structural comparison with human mitochondrial HAD
and ligand-binding model
We compared the structure of Mtb FadB2 with that of
human mitochondrial 3-hydroxyacyl-CoA dehydrogenase
(HsHAD), which has been determined in complex with NAD+
and acetoacetyl-CoA (PDB entry 1f0y; Barycki et al., 2000),
i.e. the product of the 3-hydroxy dehydrogenase reaction. The
superposition shows that in the ligand-bound state the N- and
C-terminal domains move towards each other in a subtle
closing motion around the ligands relative to the apo state of
FadB2 (Supplementary Fig. S3a).
We identified amino-acid side chains in HsHAD that
contact the ligands (4 A˚ distance cutoff) and we examined the
extent to which these contact residues are conserved in FadB2
(Fig. 3). Of the 15 residues that contact NAD within the
distance cutoff in HsHAD, ten are identical in FadB2 and 13
are similar or identical. Similarly, of the 15 residues that
contact the CoA ligand in HsHAD, 11 are identical in FadB2
(14 are similar or identical). In percentage terms, this means
that the residues predicted to contact the redox cofactor and
substrate are 66% or 73% identical, respectively, in FadB2,
compared with an overall sequence identity of 40.5% between
these two enzymes. Visualization of the structural super-
position (Supplementary Fig. S3b) illustrates a close match of
contacting side chains, despite the subtle difference in overall
conformation. For instance, Ser122, which is essential for
catalysis (Taylor et al., 2010), maps onto Ser137 of HsHAD,
while the strictly conserved His143 maps onto His158 of
HsHAD. Both of these residues are juxtaposed with the
nicotinamide group of NAD+, indicating the catalytic centre of
the enzyme. Overall, the structural analysis of FadB2 in terms
of fold, tertiary structure and the conservation of amino acids
that are observed to be in contact with the ligands in the
human mitochondrial orthologue is entirely consistent with
our previous enzymatic characterization (Taylor et al., 2010).
4. Concluding remarks
The structural features of FadB2 revealed in this study are
fully consistent with the enzymatic characterization that we
have reported previously (Taylor et al., 2010). Nevertheless,
the extensive redundancy of genes implicated in -oxidation
(and other pathways of fatty-acid metabolism) poses the
question of the functional role of FadB2 and how it may work
with other enzymes implicated in -oxidation. The structural
comparison of monofunctional FadB2 with the trifunctional
FadA–FadB complex provides clues with regard to functional
differences. Firstly, the multi-catalytic FadB cannot dimerize in
the fashion of the monofunctional enzyme; secondly, FadB2
cannot replace FadB in the trifunctional FadA–FadB complex
as it lacks the hydratase domain. This does not preclude the
action of FadB2 on products of the hydratase activity of FadB,
but given the evidence for substrate channelling within the
trifunctional complex, it is unlikely to be the dominant event.
Instead, FadB2 may preferentially interact (physically and/or
functionally) with other homologues of the fad gene family.
Interrogation of the STRING database (Szklarczyk et al.,
2017), which computes protein-interaction networks by
combining experimental data with database information and
homology relationships, suggests the enoyl-CoA hydratase
EchA8 and several thiolases of the FadA family as potential
interaction partners (Supplementary Fig. S5). These enzymes
catalyse the reaction steps preceding and subsequent to
3-hydroxy dehydrogenation, respectively (Fig. 1).
5. Related literature
The following references are cited in the supporting infor-
mation for this article: Webb & Sali (2017) and Zimmermann
et al. (2018).
Acknowledgements
GSB acknowledges support from a Personal Research Chair
from Mr James Bardrick and a Royal Society Wolfson
Research Merit Award. We thank Diamond Light Source for
access to synchrotron beamlines (BAG MX14692) and their
staff for support during experiments. Author contributions:
JAGC, GSB and KF designed the study; JAGC, RCTand AKB
generated reagents; JAGC and KF collected the data; JAGC,
SA and KF analysed the data; JAGC and KF generated the
figures; JAGC, GSB and KF wrote and edited the manuscript,
which was reviewed by all authors.
Funding information
This work is supported by funding from the Medical Research
Council (MRC; MR/S000542/1).
References
Arent, S., Christensen, C. E., Pye, V. E., Nørgaard, A. & Henriksen,
A. (2010). J. Biol. Chem. 285, 24066–24077.
Barycki, J. J., O’Brien, L. K., Strauss, A. W. & Banaszak, L. J. (2000).
J. Biol. Chem. 275, 27186–27196.
Black, P. N. & DiRusso, C. C. (1994). Biochim. Biophys. Acta, 1210,
123–145.
Bonds, A. C. & Sampson, N. S. (2018). Curr. Opin. Chem. Biol. 44, 39–
46.
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino,
R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson,
D. C. (2010). Acta Cryst. D66, 12–21.
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris,
D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., Tekaia, F.,
Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R.,
Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N.,
Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule,
research papers
Acta Cryst. (2019). D75, 101–108 Cox et al.  M. tuberculosis FadB2 107
S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream,
M. A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R.,
Squares, R., Sulston, J. E., Taylor, K., Whitehead, S. & Barrell, B. G.
(1998). Nature (London), 393, 537–544.
Eaton, S., Bartlett, K. & Pourfarzam, M. (1996). Biochem. J. 320, 345–
357.
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta
Cryst. D66, 486–501.
Fisher, M. A., Plikaytis, B. B. & Shinnick, T. M. (2002). J. Bacteriol.
184, 4025–4032.
Gagneux, S. (2012). Philos. Trans. R. Soc. London B Biol. Sci. 367,
850–859.
Ishikawa, M., Tsuchiya, D., Oyama, T., Tsunaka, Y. & Morikawa, K.
(2004). EMBO J. 23, 2745–2754.
Kabsch, W. & Sander, C. (1983). Biopolymers, 22, 2577–2637.
Karplus, P. A. & Diederichs, K. (2012). Science, 336, 1030–1033.
Kasaragod, P., Venkatesan, R., Kiema, T. R., Hiltunen, J. K. &
Wierenga, R. K. (2010). J. Biol. Chem. 285, 24089–24098.
Kim, E.-J., Kim, J., Ahn, J.-W., Kim, Y.-J., Chang, J. H. & Kim, K.-J.
(2014). J. Microbiol. Biotechnol. 24, 1636–1643.
Krissinel, E. (2015). Nucleic Acids Res. 43, W314–W319.
Lee, W., VanderVen, B. C., Fahey, R. J. & Russell, D. G. (2013). J. Biol.
Chem. 288, 6788–6800.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,
Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
Mun˜oz-Elı´as, E. J. & McKinney, J. D. (2006). Cell. Microbiol. 8, 10–22.
Murshudov, G. N., Skuba´k, P., Lebedev, A. A., Pannu, N. S., Steiner,
R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011).
Acta Cryst. D67, 355–367.
Pandey, A. K. & Sassetti, C. M. (2008). Proc. Natl Acad. Sci. USA,
105, 4376–4380.
Russell, D. G. (2007). Nature Rev. Microbiol. 5, 39–47.
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S.,
Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P.,
Jensen, L. J. & von Mering, C. (2017). Nucleic Acids Res. 45, D362–
D368.
Taylor, R. C., Brown, A. K., Singh, A., Bhatt, A. & Besra, G. S. (2010).
Microbiology, 156, 1975–1982.
VanderVen, B. C., Fahey, R. J., Lee, W., Liu, Y., Abramovitch, R. B.,
Memmott, C., Crowe, A. M., Eltis, L. D., Perola, E., Deininger,
D. D., Wang, T., Locher, C. P. & Russell, D. G. (2015). PLoS Pathog.
11, e1004679.
Venkatesan, R. & Wierenga, R. K. (2013). ACS Chem. Biol. 8, 1063–
1073.
Webb, B. & Sali, A. (2017). Methods Mol. Biol. 1654, 39–54.
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P.,
Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W.,
McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S.,
Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A. & Wilson,
K. S. (2011). Acta Cryst. D67, 235–242.
Wipperman, M. F., Sampson, N. S. & Thomas, S. T. (2014). Crit. Rev.
Biochem. Mol. Biol. 49, 269–293.
World Health Organization (2018). Global Tuberculosis Report 2018.
https://www.who.int/tb/publications/global_report/en/. Geneva:
World Health Organization.
Zimmermann, L., Stephens, A., Nam, S.-Z., Rau, D., Ku¨bler, J.,
Lozajic, M., Gabler, F., So¨ding, J., Lupas, A. N. & Alva, V. (2018). J.
Mol. Biol. 430, 2237–2243.
research papers
108 Cox et al.  M. tuberculosis FadB2 Acta Cryst. (2019). D75, 101–108
